Mavacamten

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 462 publications

Structure of the Myosin Thick Filaments in Muscle.

Structure of the Myosin Thick Filaments in Muscle.

Journal: Sub-cellular biochemistry
Published: January 20, 2026

Response to the letter to the editor concerning: 'catastrophic apical ballooning in obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report'.

Response to the letter to the editor concerning: 'catastrophic apical ballooning in obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report'.

Journal: European heart journal. Case reports
Published: January 15, 2026

Letter to the editor concerning: Catastrophic apical ballooning in obstructive hypertrophic cardiomyopathy patient treated with mavacamten.

Letter to the editor concerning: Catastrophic apical ballooning in obstructive hypertrophic cardiomyopathy patient treated with mavacamten.

Journal: European heart journal. Case reports
Published: January 15, 2026

CYP450 activity, drug interactions and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.

CYP450 activity, drug interactions and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.

Journal: Expert opinion on drug safety
Published: November 28, 2025

Cryo-EM Reveals How Cardiomyopathy Therapeutic Drugs Modulate the Myosin Motors of the Heart.

Cryo-EM Reveals How Cardiomyopathy Therapeutic Drugs Modulate the Myosin Motors of the Heart.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation.

ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation.

Journal: Circulation. Genomic and precision medicine
Published: November 12, 2025

Myosin Inhibitors for the Treatment of Obstructive Hypertrophic Cardiomyopathy: A Canadian Perspective on a First-in-Class Therapy.

Myosin Inhibitors for the Treatment of Obstructive Hypertrophic Cardiomyopathy: A Canadian Perspective on a First-in-Class Therapy.

Journal: Canadian journal of physiology and pharmacology
Published: November 12, 2025

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.

Journal: Circulation. Genomic and precision medicine
Published: November 10, 2025

Myosin inhibition partially rescues the myofibre proteome in X-linked myotubular myopathy.

Myosin inhibition partially rescues the myofibre proteome in X-linked myotubular myopathy.

Journal: JCI insight
Published: November 06, 2025

Non-invasive evaluation of left ventricular hemodynamic force abnormalities in hypertrophic cardiomyopathy: Implications for myosin inhibition.

Non-invasive evaluation of left ventricular hemodynamic force abnormalities in hypertrophic cardiomyopathy: Implications for myosin inhibition.

Journal: International journal of cardiology
Published: November 04, 2025

Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease.

Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: November 01, 2025

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: October 28, 2025
Showing 1-12 of 462

Last Updated: 02/24/2026